2. Academic Validation
  3. Computational identification of potential inhibitors targeting cdk1 in colorectal cancer

Computational identification of potential inhibitors targeting cdk1 in colorectal cancer

  • Front Chem. 2023 Nov 30:11:1264808. doi: 10.3389/fchem.2023.1264808.
Uchechukwu C Ogbodo 1,  Ojochenemi A Enejoh 2,  Chinelo H Okonkwo 3,  Pranavathiyani Gnanasekar 4,  Pauline W Gachanja 5,  Shamim Osata 6,  Halimat C Atanda 7,  Emmanuel A Iwuchukwu 8,  Ikechukwu Achilonu 8,  Olaitan I Awe 9 10
Affiliations

Affiliations

  • 1 Department of Applied Biochemistry, Nnamdi Azikiwe University, Awka, Nigeria.
  • 2 Genomics and Bioinformatics Department, National Biotechnology Development Agency, Abuja, Nigeria.
  • 3 Department of Pharmacology and Toxicology, University of Nigeria, Nsukka, Nigeria.
  • 4 Department of Bioinformatics, Pondicherry University, Puducherry, India.
  • 5 Department of Biochemistry and Biotechnology, Pwani University, Kilifi, Kenya.
  • 6 Department of Biochemistry, University of Nairobi, Nairobi, Kenya.
  • 7 Biotechnology Department, Federal University of Technology, Akure, Nigeria.
  • 8 Protein Structure-Function Research Unit, School of Molecular and Cell Biology, Faculty of Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • 9 Department of Computer Science, University of Ibadan, Ibadan, Nigeria.
  • 10 African Society for Bioinformatics and Computational Biology, Cape Town, South Africa.
PMID: 38099190 DOI: 10.3389/fchem.2023.1264808
Abstract

Introduction: Despite improved treatment options, colorectal Cancer (CRC) remains a huge public health concern with a significant impact on affected individuals. Cell cycle dysregulation and overexpression of certain regulators and checkpoint activators are important recurring events in the progression of Cancer. Cyclin-dependent kinase 1 (CDK1), a key regulator of the cell cycle component central to the uncontrolled proliferation of malignant cells, has been reportedly implicated in CRC. This study aimed to identify CDK1 inhibitors with potential for clinical drug research in CRC. Methods: Ten thousand (10,000) naturally occurring compounds were evaluated for their inhibitory efficacies against CDK1 through molecular docking studies. The stability of the lead compounds in complex with CDK1 was evaluated using molecular dynamics simulation for one thousand (1,000) nanoseconds. The top-scoring candidates' ADME characteristics and drug-likeness were profiled using SwissADME. Results: Four hit compounds, namely, spiraeoside, robinetin, 6-hydroxyluteolin, and quercetagetin were identified from molecular docking analysis to possess the least binding scores. Molecular dynamics simulation revealed that robinetin and 6-hydroxyluteolin complexes were stable within the binding pocket of the CDK1 protein. Discussion: The findings from this study provide insight into novel candidates with specific inhibitory CDK1 activities that can be further investigated through animal testing, clinical trials, and drug development research for CRC treatment.

Keywords

colorectal cancer; cyclin-dependent kinase 1; inhibitors; molecular dynamics simulation; natural compounds.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-170306
    CDK1/CDK2抑制剂
    CDK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z